NCT04700280View on ClinicalTrials.gov

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

October 28, 2021

Study Completion Date

December 27, 2021

Conditions
Primary Sjögren Syndrome
Interventions
DRUG

GLPG3970

GLPG3970 film-coated tablet.

DRUG

Placebo

Placebo film-coated tablet.

Trial Locations (10)

1135

Medical Center Harmoniya Krasy, Kyiv

4032

Debreceni Egyetem, Debrecen

11527

General Hospital of Athens Laiko, Athens

79106

Universitaetsklinikum Freiburg, Freiburg im Breisgau

85-168

Szpital Uniwersytecki nr 2 im.dr J. Biziela, Bydgoszcz

30-363

Centrum Medyczne Plejady, Krakow

20-412

ETG Lublin, Lublin

60-773

Centrum Badan Klinicznych S.C., Poznan

00-874

Medycyna Kliniczna, Warsaw

02-691

NZOZ Centrum Medyczne Reuma Park, Warsaw

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY